Open AccessThrombolysis for Central Retinal Artery Occlusion in 2020: Time Is Vision!
Author(s) -
Oana M. Dumitrascu,
Nancy J. Newman,
Valérie Biousse
Publication year - 2020
Publication title -
journal of neuro-ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.586
H-Index - 55
eISSN - 1536-5166
pISSN - 1070-8022
DOI - 10.1097/wno.0000000000001027
Subject(s) - medicine , central retinal artery occlusion , tenecteplase , thrombolysis , fibrinolytic agent , randomized controlled trial , stroke (engine) , tissue plasminogen activator , visual acuity , surgery , myocardial infarction , mechanical engineering , engineering
Acute nonarteritic central retinal artery occlusion (CRAO) is an eye stroke with poor visual prognosis and no proven effective therapies. Given advances in acute stroke care, thrombolysis in CRAO merits critical re-examination. We review the evidence for intravenous (IV) and intra-arterial (IA) tissue plasminogen activator (tPA) in CRAO management.